Fig. 23

I TEM images of E. coli cells (A), S. aureus cells (B), and drug resistant E.coli (C), before (A, B and C) and after (A-I, A-II, B-I, B-II, C-I and C-II) treatment with 20 μg/mL GQD-AgNP hybrids, II Cell viability of (a) E. coli and (b) S. aureus; the plate samples showing colonies of (c) E. coli and (d) S. aureus, III (a,b) The effect of the MSN-AuNPs based antibacterial system on the biofilm destruction of B. subtilis. (a) Pictures of crystal-violet-stained the remaining biofilms. (b) The remaining biofilms were quantified by crystal violet staining. (c,d) The effect of the MSN-AuNPs based antibacterial system on the biofilm formation of B. subtilis. (c) Pictures of crystal-violet-stained the generated biofilms. (d) Quantification of the generated biofilms by crystal violet staining, IV Schematic illustration of nanozyme-catalysed antibacterial performance of CuO NRs